Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBITDA: 2009-2024

Historic EBITDA for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to -$123.5 million.

  • Myriad Genetics' EBITDA fell 16.50% to -$23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$420.5 million, marking a year-over-year decrease of 263.13%. This contributed to the annual value of -$123.5 million for FY2024, which is 52.02% up from last year.
  • According to the latest figures from FY2024, Myriad Genetics' EBITDA is -$123.5 million, which was up 52.02% from -$257.4 million recorded in FY2023.
  • In the past 5 years, Myriad Genetics' EBITDA registered a high of -$123.5 million during FY2024, and its lowest value of -$289.7 million during FY2020.
  • Its 3-year average for EBITDA is -$173.8 million, with a median of -$140.6 million in 2022.
  • In the last 5 years, Myriad Genetics' EBITDA crashed by 3,148.68% in 2020 and then surged by 52.02% in 2024.
  • Over the past 5 years, Myriad Genetics' EBITDA (Yearly) stood at -$231.7 million in 2020, then reached -$289.7 million in 2020, then skyrocketed by 34.24% to -$190.5 million in 2021, then increased by 26.19% to -$140.6 million in 2022, then tumbled by 83.07% to -$257.4 million in 2023, then skyrocketed by 52.02% to -$123.5 million in 2024.